Abstract
Development of skin leukoderma (LEU) is associated with a positive response to immunotherapy with checkpoint inhibitors in melanoma patients. Thus, we hypothesized that T cell hallmarks in patients who developed LEU could predict patient’s response to checkpoint inhibitors. To this extend, we analyzed T cells from peripheral blood of melanoma patients, classified as responders with LEU, responders without LEU, or no responders, throughout the treatment with anti-PD1 antibodies. We found that occurrence of LEU was associated with reduction of MAIT, Th17 and T-reg cell frequency in the blood.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
